(Q54183735)

English

A randomized controlled trial of adjunctive Bunchang Naoxintong Capsule (步长脑心通胶囊) versus maintenance dose clopidogrel in patients with CYP2C19*2 polymorphism.

scientific article published on 27 November 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/25428337

A randomized controlled trial of adjunctive Bunchang Naoxintong Capsule (步长脑心通胶囊) versus maintenance dose clopidogrel in patients with CYP2C19*2 polymorphism. (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/25428337

1 reference

based on heuristic

inferred from title

author name string

Hui Chen

1

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/25428337

Xiao-Ying Wu

2

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/25428337

Hong-Xia Wu

3

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/25428337

Huan Wang

4

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/25428337

publication date

27 November 2014

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/25428337

Chinese Journal of Integrated Traditional and Western Medicine

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/25428337

20

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/25428337

12

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/25428337

894-902

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/25428337

https://scigraph.springernature.com/pub.10.1007/s11655-014-2023-z

0 references

Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes

1 reference

https://api.crossref.org/works/10.1007%2FS11655-014-2023-Z

21 January 2018

Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study

1 reference

https://api.crossref.org/works/10.1007%2FS11655-014-2023-Z

21 January 2018

Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy

1 reference

https://api.crossref.org/works/10.1007%2FS11655-014-2023-Z

21 January 2018

Cytochrome p-450 polymorphisms and response to clopidogrel

1 reference

https://api.crossref.org/works/10.1007%2FS11655-014-2023-Z

21 January 2018

Genetic polymorphism of cytochrome P450 2C19 in Mexican Americans: a cross-ethnic comparative study

1 reference

https://api.crossref.org/works/10.1007%2FS11655-014-2023-Z

21 January 2018

ACCF/AHA clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Ca

1 reference

https://api.crossref.org/works/10.1007%2FS11655-014-2023-Z

21 January 2018

Meta-analysis of cytochrome P450 2C19 polymorphism and risk of adverse clinical outcomes among coronary artery disease patients of different ethnic groups treated with clopidogrel

1 reference

https://api.crossref.org/works/10.1007%2FS11655-014-2023-Z

21 January 2018

High maintenance dosage of clopidogrel is associated with a reduced risk of stent thrombosis in clopidogrel-resistant patients

1 reference

https://api.crossref.org/works/10.1007%2FS11655-014-2023-Z

21 January 2018

Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Pati

1 reference

https://api.crossref.org/works/10.1007%2FS11655-014-2023-Z

21 January 2018

Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1007%2FS11655-014-2023-Z

21 January 2018

Incidence, correlates, and clinical impact of nuisance bleeding after antiplatelet therapy for patients with drug-eluting stents.

1 reference

https://api.crossref.org/works/10.1007%2FS11655-014-2023-Z

21 January 2018

Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement

1 reference

https://api.crossref.org/works/10.1007%2FS11655-014-2023-Z

21 January 2018

Prasugrel versus clopidogrel in patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1007%2FS11655-014-2023-Z

21 January 2018

The effect of St John's Wort on the pharmacodynamic response of clopidogrel in hyporesponsive volunteers and patients: increased platelet inhibition by enhancement of CYP3A4 metabolic activity

1 reference

https://api.crossref.org/works/10.1007%2FS11655-014-2023-Z

21 January 2018

Efficacy of dual antiplatelet therapy combined with Naoxintong capsules [see text] following coronary microembolization induced by homologous microthrombi in rats

1 reference

https://api.crossref.org/works/10.1007%2FS11655-014-2023-Z

21 January 2018

The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance

1 reference

https://api.crossref.org/works/10.1007%2FS11655-014-2023-Z

21 January 2018

Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance

1 reference

https://api.crossref.org/works/10.1007%2FS11655-014-2023-Z

21 January 2018

Calcium-channel blockers reduce the antiplatelet effect of clopidogrel

1 reference

https://api.crossref.org/works/10.1007%2FS11655-014-2023-Z

21 January 2018

Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study

1 reference

https://api.crossref.org/works/10.1007%2FS11655-014-2023-Z

21 January 2018

The drug-drug interaction between proton pump inhibitors and clopidogrel

1 reference

https://api.crossref.org/works/10.1007%2FS11655-014-2023-Z

21 January 2018

Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study

1 reference

https://api.crossref.org/works/10.1007%2FS11655-014-2023-Z

21 January 2018

The influence of St John's Wort on CYP2C19 activity with respect to genotype

1 reference

https://api.crossref.org/works/10.1007%2FS11655-014-2023-Z

21 January 2018

Trade herbal products and induction of CYP2C19 and CYP2E1 in cultured human hepatocytes

1 reference

https://api.crossref.org/works/10.1007%2FS11655-014-2023-Z

21 January 2018

Herbal medicine yin zhi huang induces CYP3A4-mediated sulfoxidation and CYP2C19-dependent hydroxylation of omeprazole

1 reference

https://api.crossref.org/works/10.1007%2FS11655-014-2023-Z

21 January 2018

St John's wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole

1 reference

https://api.crossref.org/works/10.1007%2FS11655-014-2023-Z

21 January 2018

Pharmacogenetics and herb-drug interactions: experience with Ginkgo biloba and omeprazole

1 reference

https://api.crossref.org/works/10.1007%2FS11655-014-2023-Z

21 January 2018

Buyang Huanwu decoction ameliorates coronary heart disease with Qi deficiency and blood stasis syndrome by reducing CRP and CD40 in rats

1 reference

https://api.crossref.org/works/10.1007%2FS11655-014-2023-Z

21 January 2018

Aggregation of Blood Platelets by Adenosine Diphosphate and its Reversal

1 reference

https://api.crossref.org/works/10.1007%2FS11655-014-2023-Z

21 January 2018

Chinese herbal medicine Naoxintong capsule combined with dual antiplatelet therapy in a rat model of coronary microembolization induced by homologous microthrombi.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25428337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25428337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study

1 reference

https://pubmed.ncbi.nlm.nih.gov/25428337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In Vitro Assessment of Cytochrome P450 2C19 Potential of Naoxintong

1 reference

https://pubmed.ncbi.nlm.nih.gov/25428337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Impact of CYP2C19 polymorphism and smoking on response to clopidogrel in patients with stable coronary artery disease.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25428337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The balance between anti-ischemic efficacy and bleeding risk of antithrombotic therapy in percutaneous coronary intervention: a Yin-Yang paradigm.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25428337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Biological effect of increased maintenance dose of clopidogrel in cardiovascular outpatients and influence of the cytochrome P450 2C19*2 allele on clopidogrel responsiveness

1 reference

https://pubmed.ncbi.nlm.nih.gov/25428337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Relationships of blood stasis syndrome, CYP2C19 gene polymorphism with clopidogrel resistance and post-PCI prognosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/25428337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently

1 reference

https://pubmed.ncbi.nlm.nih.gov/25428337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Genetic variation in metabolizing enzyme and transporter genes: comprehensive assessment in 3 major East Asian subpopulations with comparison to Caucasians and Africans

1 reference

https://pubmed.ncbi.nlm.nih.gov/25428337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/25428337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of Adjunctive Naoxintong versus Clopidogrel in Volunteers with the CYP2C19*2 Gene Mutation Accompanied with Qi Deficiency and Blood Stasis Constitution

1 reference

https://pubmed.ncbi.nlm.nih.gov/25428337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S11655-014-2023-Z

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/25428337

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/25428337

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54183735&oldid=1442561276"